Switch to:
Also traded in: Brazil, Germany, Mexico, Switzerland

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.05
TMO's Cash to Debt is ranked lower than
96% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.88 vs. TMO: 0.05 )
Ranked among companies with meaningful Cash to Debt only.
TMO' s Cash to Debt Range Over the Past 10 Years
Min: 0.04  Med: 0.37 Max: 2.34
Current: 0.05
0.04
2.34
Equity to Asset 0.50
TMO's Equity to Asset is ranked lower than
64% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.58 vs. TMO: 0.50 )
Ranked among companies with meaningful Equity to Asset only.
TMO' s Equity to Asset Range Over the Past 10 Years
Min: 0.32  Med: 0.56 Max: 0.75
Current: 0.5
0.32
0.75
Interest Coverage 5.62
TMO's Interest Coverage is ranked lower than
82% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 83.10 vs. TMO: 5.62 )
Ranked among companies with meaningful Interest Coverage only.
TMO' s Interest Coverage Range Over the Past 10 Years
Min: 4.66  Med: 6.56 Max: 14.24
Current: 5.62
4.66
14.24
F-Score: 7
Z-Score: 2.83
M-Score: -2.57
WACC vs ROIC
7.96%
7.07%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 13.68
TMO's Operating margin (%) is ranked higher than
80% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.48 vs. TMO: 13.68 )
Ranked among companies with meaningful Operating margin (%) only.
TMO' s Operating margin (%) Range Over the Past 10 Years
Min: 6.38  Med: 11.56 Max: 14.82
Current: 13.68
6.38
14.82
Net-margin (%) 11.35
TMO's Net-margin (%) is ranked higher than
81% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.51 vs. TMO: 11.35 )
Ranked among companies with meaningful Net-margin (%) only.
TMO' s Net-margin (%) Range Over the Past 10 Years
Min: 4.46  Med: 9.58 Max: 11.64
Current: 11.35
4.46
11.64
ROE (%) 9.51
TMO's ROE (%) is ranked higher than
68% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.35 vs. TMO: 9.51 )
Ranked among companies with meaningful ROE (%) only.
TMO' s ROE (%) Range Over the Past 10 Years
Min: 2.02  Med: 7.23 Max: 10.13
Current: 9.51
2.02
10.13
ROA (%) 4.78
TMO's ROA (%) is ranked higher than
70% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.30 vs. TMO: 4.78 )
Ranked among companies with meaningful ROA (%) only.
TMO' s ROA (%) Range Over the Past 10 Years
Min: 1.32  Med: 4.49 Max: 5.52
Current: 4.78
1.32
5.52
ROC (Joel Greenblatt) (%) 47.80
TMO's ROC (Joel Greenblatt) (%) is ranked higher than
82% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -10.22 vs. TMO: 47.80 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
TMO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 16.16  Med: 41.38 Max: 62.88
Current: 47.8
16.16
62.88
Revenue Growth (3Y)(%) 7.30
TMO's Revenue Growth (3Y)(%) is ranked higher than
64% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.80 vs. TMO: 7.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
TMO' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -12.9  Med: 7.5 Max: 18.7
Current: 7.3
-12.9
18.7
EBITDA Growth (3Y)(%) 13.90
TMO's EBITDA Growth (3Y)(%) is ranked higher than
73% of the 123 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. TMO: 13.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
TMO' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -30.1  Med: 13.9 Max: 40.9
Current: 13.9
-30.1
40.9
EPS Growth (3Y)(%) 12.90
TMO's EPS Growth (3Y)(%) is ranked higher than
73% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. TMO: 12.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
TMO' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -43.5  Med: 12.8 Max: 74.6
Current: 12.9
-43.5
74.6
» TMO's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-21)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

TMO Guru Trades in Q3 2015

John Burbank 27,500 sh (New)
Manning & Napier Advisors, Inc 504,380 sh (New)
Paul Tudor Jones 5,500 sh (New)
Vanguard Health Care Fund 3,081,000 sh (+15.01%)
John Rogers 607,166 sh (+3.74%)
Pioneer Investments 2,196,122 sh (+1.15%)
First Eagle Investment 200 sh (unchged)
Ruane Cunniff 2,873 sh (unchged)
Jim Simons Sold Out
Andreas Halvorsen Sold Out
Dodge & Cox 52,902 sh (-1.67%)
PRIMECAP Management 5,401,253 sh (-2.16%)
Scott Black 58,434 sh (-2.68%)
David Dreman 14,000 sh (-4.32%)
Larry Robbins 8,511,204 sh (-8.08%)
John Griffin 1,090,000 sh (-8.40%)
Signature Select Canadian Fund 104,800 sh (-13.39%)
Mairs and Power 1,885 sh (-19.27%)
Ray Dalio 30,504 sh (-30.23%)
Mario Gabelli 16,450 sh (-37.81%)
First Pacific Advisors 1,933,550 sh (-43.93%)
Steven Romick 1,774,700 sh (-44.19%)
Steven Cohen 1,800 sh (-94.59%)
» More
Q4 2015

TMO Guru Trades in Q4 2015

Ken Fisher 1,867 sh (New)
Dodge & Cox 571,892 sh (+981.04%)
Manning & Napier Advisors, Inc 585,510 sh (+16.09%)
Pioneer Investments 2,243,048 sh (+2.14%)
John Rogers 610,985 sh (+0.63%)
First Eagle Investment 200 sh (unchged)
Vanguard Health Care Fund 3,081,000 sh (unchged)
Ruane Cunniff 2,873 sh (unchged)
Samuel Isaly 141,000 sh (unchged)
John Burbank Sold Out
Ray Dalio Sold Out
David Dreman Sold Out
Paul Tudor Jones Sold Out
John Griffin Sold Out
PRIMECAP Management 5,399,890 sh (-0.03%)
Mario Gabelli 16,165 sh (-1.73%)
First Pacific Advisors 1,832,410 sh (-5.23%)
Steven Romick 1,638,180 sh (-7.69%)
Mairs and Power 1,735 sh (-7.96%)
Steven Cohen 1,500 sh (-16.67%)
Larry Robbins 5,933,331 sh (-30.29%)
Scott Black 13,328 sh (-77.19%)
» More
Q1 2016

TMO Guru Trades in Q1 2016

David Dreman 10,137 sh (New)
Diamond Hill Capital 580,922 sh (New)
Joel Greenblatt 4,687 sh (New)
Mario Gabelli 32,720 sh (+102.41%)
Vanguard Health Care Fund 4,315,800 sh (+40.08%)
Manning & Napier Advisors, Inc 687,890 sh (+17.49%)
Pioneer Investments 2,353,745 sh (+4.94%)
PRIMECAP Management 5,439,360 sh (+0.73%)
First Eagle Investment 200 sh (unchged)
Samuel Isaly 141,000 sh (unchged)
Ruane Cunniff Sold Out
Steven Cohen Sold Out
Scott Black 13,031 sh (-2.23%)
Mairs and Power 1,683 sh (-3.00%)
Dodge & Cox 550,892 sh (-3.67%)
First Pacific Advisors 1,689,060 sh (-7.82%)
Steven Romick 1,507,820 sh (-7.96%)
John Rogers 540,015 sh (-11.62%)
Ken Fisher 1,642 sh (-12.05%)
Signature Select Canadian Fund 86,200 sh (-17.75%)
Larry Robbins 3,610,552 sh (-39.15%)
» More
Q2 2016

TMO Guru Trades in Q2 2016

Paul Tudor Jones 3,600 sh (New)
Ray Dalio 12,466 sh (New)
Pioneer Investments 2,593,804 sh (+10.20%)
Mairs and Power 1,786 sh (+6.12%)
First Pacific Advisors 1,788,830 sh (+5.91%)
Vanguard Health Care Fund 4,315,800 sh (unchged)
First Eagle Investment 200 sh (unchged)
Samuel Isaly 141,000 sh (unchged)
Scott Black Sold Out
Ken Fisher Sold Out
Mario Gabelli 32,545 sh (-0.53%)
John Rogers 536,549 sh (-0.64%)
Diamond Hill Capital 574,065 sh (-1.18%)
PRIMECAP Management 5,362,400 sh (-1.41%)
David Dreman 9,811 sh (-3.22%)
Dodge & Cox 526,642 sh (-4.40%)
Steven Romick 1,415,820 sh (-6.10%)
Manning & Napier Advisors, Inc 631,340 sh (-8.22%)
Larry Robbins 2,858,240 sh (-20.84%)
Joel Greenblatt 1,790 sh (-61.81%)
» More
» Details

Insider Trades

Latest Guru Trades with TMO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NYSE:A, NYSE:LH, OTCPK:SSMXY, NYSE:DGX, NAS:IDXX, NYSE:Q, NAS:DXCM, OTCPK:ERFSF, NAS:QGEN, NYSE:PKI, OTCPK:BMXMF, NYSE:BIO.B, NAS:ICLR, NYSE:CRL, NAS:CPHD, NYSE:ALR, NAS:VWR, NAS:PRXL, NAS:BRKR, NAS:PRAH » details
Traded in other countries:TMOS34.Brazil, TN8.Germany, TMO.Mexico, TFS.Switzerland,
Thermo Fisher Scientific Inc offers analytical instruments, laboratory equipment, software, services, consumables, reagents, chemicals, and supplies to pharmaceutical and biotech companies, hospitals and clinical diagnostic labs.

Thermo Fisher Scientific Inc is a Delaware corporation and was incorporated in 1956. The Company completed its initial public offering in 1967 and was listed on the New York Stock Exchange in 1980. In November 2006, Thermo Electron Corporation merged with Fisher Scientific International Inc. to create Thermo Fisher. The Company completed its initial public offering in 1967. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It serves customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental, industrial quality and process control settings. The Company's continuing operations fall into three business segments: Analytical Technologies, Specialty Diagnostics, and Laboratory Products and Services. Analytical Technologies segment provides offerings of instruments, reagents, consumables, software and services that are used for applications in the laboratory, on the production line and in the field. These products are used by customers in all four of the company's key end markets: healthcare and diagnostics; pharmaceutical and biotechnology; academic and government; and industrial and applied. This segment includes four primary businesses - Chromatography and Mass Spectrometry, Chemical Analysis, Environmental and Process Instruments, and Biosciences. Specialty Diagnostics segment provides diagnostic test kits, reagents, culture media, instruments and associated products used to increase the speed and accuracy of diagnoses. Its chemical analysis products fall into three main categories: materials and minerals; molecular spectroscopy; and portable analytical instruments. Customers use these products to quickly and accurately analyze the composition of materials in small samples to optimize workflows in academic, life sciences, pharmaceutical, and industrial applications. These products are used by customers in healthcare, clinical, pharmaceutical, industrial and food safety laboratories. Laboratory Products and Services segment provides virtually everything needed for the laboratory, including a combination of self-manufactured and sourced products and an extensive service offering. These products and services are used by customers in pharmaceutical, biotechnology, academic, government and other research and industrial markets, as well as the clinical laboratory. The Company serves their customers through four brands, Thermo Scientific, Life Technologies, Fisher Scientific and Unity Lab Services. The Company markets and sells its products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors and various catalogs. It encounters aggressive and able competition in virtually all of the markets it serves. It is subject to various laws and

Top Ranked Articles about Thermo Fisher Scientific Inc

5 Stocks Hit 52-Week High Prices Thermo Fisher and Goldman Sachs among companies with rising prices
According to GuruFocus' list of 52-week highs, these guru stocks have reached their historical high prices. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 31.87
TMO's P/E(ttm) is ranked higher than
51% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.60 vs. TMO: 31.87 )
Ranked among companies with meaningful P/E(ttm) only.
TMO' s P/E(ttm) Range Over the Past 10 Years
Min: 12.67  Med: 25.83 Max: 62.79
Current: 31.87
12.67
62.79
Forward P/E 17.42
TMO's Forward P/E is ranked higher than
79% of the 42 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.74 vs. TMO: 17.42 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 31.74
TMO's PE(NRI) is ranked higher than
51% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.47 vs. TMO: 31.74 )
Ranked among companies with meaningful PE(NRI) only.
TMO' s PE(NRI) Range Over the Past 10 Years
Min: 13.48  Med: 25.83 Max: 62.07
Current: 31.74
13.48
62.07
Price/Owner Earnings (ttm) 23.20
TMO's Price/Owner Earnings (ttm) is ranked higher than
66% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.42 vs. TMO: 23.20 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
TMO' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 9.21  Med: 18.99 Max: 74.79
Current: 23.2
9.21
74.79
P/B 2.96
TMO's P/B is ranked higher than
60% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.47 vs. TMO: 2.96 )
Ranked among companies with meaningful P/B only.
TMO' s P/B Range Over the Past 10 Years
Min: 0.83  Med: 1.61 Max: 2.96
Current: 2.96
0.83
2.96
P/S 3.64
TMO's P/S is ranked lower than
53% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.27 vs. TMO: 3.64 )
Ranked among companies with meaningful P/S only.
TMO' s P/S Range Over the Past 10 Years
Min: 1.25  Med: 2.26 Max: 3.64
Current: 3.64
1.25
3.64
PFCF 23.64
TMO's PFCF is ranked higher than
51% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.45 vs. TMO: 23.64 )
Ranked among companies with meaningful PFCF only.
TMO' s PFCF Range Over the Past 10 Years
Min: 10.23  Med: 20.18 Max: 31.02
Current: 23.64
10.23
31.02
POCF 20.19
TMO's POCF is ranked lower than
56% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.96 vs. TMO: 20.19 )
Ranked among companies with meaningful POCF only.
TMO' s POCF Range Over the Past 10 Years
Min: 8.74  Med: 17.26 Max: 25.65
Current: 20.19
8.74
25.65
EV-to-EBIT 31.42
TMO's EV-to-EBIT is ranked lower than
66% of the 94 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.20 vs. TMO: 31.42 )
Ranked among companies with meaningful EV-to-EBIT only.
TMO' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.9  Med: 21.9 Max: 64.9
Current: 31.42
10.9
64.9
EV-to-EBITDA 18.46
TMO's EV-to-EBITDA is ranked lower than
57% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 16.73 vs. TMO: 18.46 )
Ranked among companies with meaningful EV-to-EBITDA only.
TMO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.8  Med: 13.8 Max: 32.6
Current: 18.46
6.8
32.6
PEG 1.78
TMO's PEG is ranked higher than
73% of the 37 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. TMO: 1.78 )
Ranked among companies with meaningful PEG only.
TMO' s PEG Range Over the Past 10 Years
Min: 0.48  Med: 1.73 Max: 5.56
Current: 1.78
0.48
5.56
Shiller P/E 48.79
TMO's Shiller P/E is ranked lower than
55% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 42.43 vs. TMO: 48.79 )
Ranked among companies with meaningful Shiller P/E only.
TMO' s Shiller P/E Range Over the Past 10 Years
Min: 20.88  Med: 40.12 Max: 62.7
Current: 48.79
20.88
62.7
Current Ratio 1.15
TMO's Current Ratio is ranked lower than
84% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.43 vs. TMO: 1.15 )
Ranked among companies with meaningful Current Ratio only.
TMO' s Current Ratio Range Over the Past 10 Years
Min: 0.9  Med: 2.26 Max: 3.83
Current: 1.15
0.9
3.83
Quick Ratio 0.77
TMO's Quick Ratio is ranked lower than
85% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. TMO: 0.77 )
Ranked among companies with meaningful Quick Ratio only.
TMO' s Quick Ratio Range Over the Past 10 Years
Min: 0.61  Med: 1.63 Max: 3.4
Current: 0.77
0.61
3.4
Days Inventory 77.61
TMO's Days Inventory is ranked higher than
56% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 88.85 vs. TMO: 77.61 )
Ranked among companies with meaningful Days Inventory only.
TMO' s Days Inventory Range Over the Past 10 Years
Min: 65.13  Med: 69.62 Max: 125.07
Current: 77.61
65.13
125.07
Days Sales Outstanding 56.16
TMO's Days Sales Outstanding is ranked higher than
57% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 64.52 vs. TMO: 56.16 )
Ranked among companies with meaningful Days Sales Outstanding only.
TMO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.89  Med: 53.81 Max: 134.07
Current: 56.16
50.89
134.07
Days Payable 32.26
TMO's Days Payable is ranked lower than
74% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.15 vs. TMO: 32.26 )
Ranked among companies with meaningful Days Payable only.
TMO' s Days Payable Range Over the Past 10 Years
Min: 31.3  Med: 32.52 Max: 103.55
Current: 32.26
31.3
103.55

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.38
TMO's Dividend Yield is ranked lower than
91% of the 77 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.12 vs. TMO: 0.38 )
Ranked among companies with meaningful Dividend Yield only.
TMO' s Dividend Yield Range Over the Past 10 Years
Min: 0.22  Med: 0.49 Max: 0.86
Current: 0.38
0.22
0.86
Dividend Payout 0.12
TMO's Dividend Payout is ranked higher than
96% of the 54 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.35 vs. TMO: 0.12 )
Ranked among companies with meaningful Dividend Payout only.
TMO' s Dividend Payout Range Over the Past 10 Years
Min: 0.1  Med: 0.15 Max: 0.22
Current: 0.12
0.1
0.22
Dividend Growth (3y) 3.60
TMO's Dividend Growth (3y) is ranked lower than
63% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. TMO: 3.60 )
Ranked among companies with meaningful Dividend Growth (3y) only.
TMO' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 3.6
Current: 3.6
0
3.6
Forward Dividend Yield 0.38
TMO's Forward Dividend Yield is ranked lower than
87% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.33 vs. TMO: 0.38 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 0.38
TMO's Yield on cost (5-Year) is ranked lower than
94% of the 95 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. TMO: 0.38 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
TMO' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.22  Med: 0.49 Max: 0.86
Current: 0.38
0.22
0.86
3-Year Average Share Buyback Ratio -3.80
TMO's 3-Year Average Share Buyback Ratio is ranked higher than
56% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.80 vs. TMO: -3.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TMO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -37.3  Med: -1.3 Max: 4.4
Current: -3.8
-37.3
4.4

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.42
TMO's Price/Projected FCF is ranked higher than
71% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.04 vs. TMO: 1.42 )
Ranked among companies with meaningful Price/Projected FCF only.
TMO' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.65  Med: 1.3 Max: 43.46
Current: 1.42
0.65
43.46
Price/DCF (Earnings Based) 1.37
TMO's Price/DCF (Earnings Based) is ranked higher than
76% of the 17 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.08 vs. TMO: 1.37 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.60
TMO's Price/Median PS Value is ranked lower than
82% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.05 vs. TMO: 1.60 )
Ranked among companies with meaningful Price/Median PS Value only.
TMO' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.37  Med: 0.91 Max: 1.59
Current: 1.6
0.37
1.59
Price/Peter Lynch Fair Value 1.89
TMO's Price/Peter Lynch Fair Value is ranked higher than
71% of the 24 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.27 vs. TMO: 1.89 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
TMO' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.59  Med: 1.75 Max: 14.2
Current: 1.89
0.59
14.2
Earnings Yield (Greenblatt) (%) 3.16
TMO's Earnings Yield (Greenblatt) (%) is ranked higher than
70% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.00 vs. TMO: 3.16 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TMO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.5  Med: 4.6 Max: 9.1
Current: 3.16
1.5
9.1
Forward Rate of Return (Yacktman) (%) 19.91
TMO's Forward Rate of Return (Yacktman) (%) is ranked higher than
80% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.43 vs. TMO: 19.91 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
TMO' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 6.7  Med: 21.1 Max: 35.5
Current: 19.91
6.7
35.5

More Statistics

Revenue (TTM) (Mil) $17,606
EPS (TTM) $ 4.99
Beta0.99
Short Percentage of Float1.32%
52-Week Range $117.10 - 160.68
Shares Outstanding (Mil)394.26

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 18,043 19,474 20,278
EPS ($) 7.32 8.21 7.56
EPS w/o NRI ($) 7.32 8.21 7.56
EPS Growth Rate
(3Y to 5Y Estimate)
10.92%
Dividends Per Share ($) 0.62 0.66 0.74
» More Articles for TMO

Headlines

Articles On GuruFocus.com
5 Stocks Hit 52-Week High Prices Jul 11 2016 
5 Companies Achieve 52-Week Highs Jun 07 2016 
Market-Beating Vanguard Health Care Fund Adds Shares to 5 Positions May 03 2016 
Vanguard Boosts Stake in Incyte in 1st Quarter May 02 2016 
Steven Romick Sells Microsoft, Walgreens, CVS Jan 20 2016 
Weekly 52-Week Highs Highlight: Kroger Co., Harris Corporation, Thermo Fisher Scientific, Delhaize G Dec 26 2015 
Should You Wait to Bet on Agilent Technologies? Dec 20 2015 
First Pacific Advisors Slashes Stake in CVS Health Dec 17 2015 
Health Care Stocks Play Prominent Roles in Steven Romick's Transactions Dec 15 2015 
Steven Romick Sells CVS, Buys United Technologies Oct 27 2015 

More From Other Websites
Bullish and Bearish Reversals for the Week Sep 26 2016
Thermo Fisher Scientific Joins Sepsis Alliance in Support of Sepsis Awareness Month Sep 26 2016
THERMO FISHER SCIENTIFIC INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 23 2016
The Cooper Companies Set to Join the S&P 500; Northwestern and NuVasive to Join S&P MidCap 400; SPS... Sep 20 2016
Thermo Fisher Adds FEI Co., Inorganic Expansion Continues Sep 20 2016
Thermo Fisher Scientific Completes Acquisition of FEI Company Sep 19 2016
Thermo Fisher Scientific Completes Acquisition of FEI Company Sep 19 2016
THERMO FISHER SCIENTIFIC INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Sep 19 2016
Automating the Extraction of DNA, RNA and Proteins Sep 19 2016
THERMO FISHER SCIENTIFIC INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 15 2016
Thermo Fisher Scientific Prices Offering of Senior Notes Sep 14 2016
Thermo Fisher Scientific Prices Offering of Senior Notes Sep 14 2016
Thermo Fisher Scientific Opens New Global Headquarters Sep 12 2016
THERMO FISHER SCIENTIFIC INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Sep 12 2016
Thermo Fisher downgraded by Cleveland Research Sep 09 2016
Thermo Fisher Scientific Opens New State-of-the Art Clinical Services Facility in South Korea Sep 09 2016
THERMO FISHER SCIENTIFIC INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 08 2016
ETF’s with exposure to Thermo Fisher Scientific, Inc. : September 8, 2016 Sep 08 2016
Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes Sep 07 2016
Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes Sep 07 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)